Several analyst reports set the price target for Teleflex Incorporated (TFX) at $252.50. While the company's fourth-quarter earnings conference is scheduled, strategic financial insights are expected on February 27. Despite this, disappointing results negatively impacted the company's stock, making it fall short of expectations. Various asset management companies, including Mirae Asset Global and Lecap Asset Management, have increased their stake in the TFX. At the same time, an investigation has been initiated into the company by Glancy Prongay & Murray LLP. Teleflex's shares recently hit a new 1-year low, evoking discussions about whether it might be time to sell. Despite the low Share price, Teleflex's share purchase has not ceased; both Robeco Institutional Asset Management and Boston Trust Walden Corp purchased significant shares. Reports show Teleflex's stock has been underperforming compared to the wider healthcare sector, despite topping third-quarter earnings. Key disappointments include a lowered revenue outlook for 2024 and declining shareholder returns. On a positive note, Teleflex reported a third-quarter revenue increase and implemented a share buyback. Furthermore, the company completed Palette Life Sciences acquisition, giving it a boost in its urology portfolio.
Teleflex Incorporated TFX News Analytics from Tue, 29 Oct 2013 07:00:00 GMT to Sat, 15 Feb 2025 06:40:26 GMT -
Rating -6
- Innovation 1
- Information 7
- Rumor -4
